Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells

McNeil, 1991, Immunology and clinical importance of antiphospholipid antibodies, Adv. Immunol., 49, 193, 10.1016/S0065-2776(08)60777-4 Bevers, 1991, Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin, Thromb. Haemostasis, 66, 629, 10.1055/s-0038-1646476 Cervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum., 46, 1019, 10.1002/art.10187 Mehdi, 2010, Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future, Eur. J. Clin. Invest., 40, 451, 10.1111/j.1365-2362.2010.02281.x Pierangeli, 2007, New targeted therapies for treatment of thrombosis in antiphospholipid syndrome, Expet Rev. Mol. Med., 9, 1, 10.1017/S1462399407000506 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemostasis, 4, 295, 10.1111/j.1538-7836.2006.01753.x Ma, 2000, High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II, J. Biol. Chem., 275, 15541, 10.1074/jbc.275.20.15541 Kaplanski, 2000, Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis, Arthritis Rheum., 43, 55, 10.1002/1529-0131(200001)43:1<55::AID-ANR8>3.0.CO;2-M Vega-Ostertag, 2005, Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies, Arthritis Rheum., 52, 1545, 10.1002/art.21009 Patsouras, 2019, Differential CpG methylation of the promoter of interleukin 8 and the first intron of tissue factor in Antiphospholipid syndrome, J. Autoimmun., 102, 159, 10.1016/j.jaut.2019.05.001 Soltesz, 2008, Immunological features of primary anti- phospholipid syndrome in connection with endothelial dysfunction, Rheumatology, 47, 1628, 10.1093/rheumatology/ken349 Forastiero, 2005, Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies, Lupus, 14, 129, 10.1191/0961203305lu2048oa Dunoyer-Geindre, 2002, NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies, Thromb. Haemostasis, 88, 851, 10.1055/s-0037-1613313 Hanly, 1996, Beta 2-glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells, J. Rheumatol., 23, 1543 Zhang, 2005, Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies, Blood, 105, 1964, 10.1182/blood-2004-05-1708 Sacharidou, 2018, Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium, Blood, 131, 2097, 10.1182/blood-2017-11-814681 Holers, 2002, Complement C3 activation is required for antiphospholipid antibody-induced fetal loss, J. Exp. Med., 195, 211, 10.1084/jem.200116116 Kim, 2018, Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies, Ann. Rheum. Dis., 77, 549, 10.1136/annrheumdis-2017-212224 Erkan, 2016, The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome, Turk. J. Haematol., 33, 1, 10.4274/tjh.2015.0197 Sorice, 2007, Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts, Arthritis Rheum., 56, 2687, 10.1002/art.22802 Satta, 2011, Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies, Blood, 117, 5523, 10.1182/blood-2010-11-316158 Allen, 2012, A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies, Blood, 119, 884, 10.1182/blood-2011-03-344671 Curtis, 2009, p38 mitogen- activated protein kinase targets the production of proinflammatory endothelial microparticles, J. Thromb. Haemostasis, 7, 701, 10.1111/j.1538-7836.2009.03304.x Raschi, 2014, beta2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti- phospholipid-mediated thrombosis, J. Autoimmun., 55, 42, 10.1016/j.jaut.2014.03.001 Patsouras, 2015, Elevated expression of platelet-derived chemokines in patients with antiphospholipid syndrome, J. Autoimmun., 65, 30, 10.1016/j.jaut.2015.08.001 Sikara, 2010, {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome, Blood, 115, 713, 10.1182/blood-2009-03-206367 Vlachoyiannopoulos, 2010, A novel mechanism of thrombosis in antiphospholipid antibody syndrome, J. Autoimmun., 35, 248, 10.1016/j.jaut.2010.06.015 Hamid, 2007, Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome, Ann. Rheum. Dis., 66, 1000, 10.1136/ard.2006.063909 Jin, 2013, A high-resolution map of the three-dimensional chromatin interactome in human cells, Nature, 503, 290, 10.1038/nature12644 Morikawa, 2011, ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif, Nucleic Acids Res., 39, 8712, 10.1093/nar/gkr572 Baudin, 2007, A protocol for isolation and culture of human umbilical vein endothelial cells, Nat. Protoc., 2, 481, 10.1038/nprot.2007.54 FastQC, 2010 Afgan, 2018, The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update, Nucleic Acids Res., 46, W537, 10.1093/nar/gky379 Trapnell, 2009, TopHat: discovering splice junctions with RNA-Seq, Bioinformatics, 25, 1105, 10.1093/bioinformatics/btp120 Anders, 2015, HTSeq--a Python framework to work with high- throughput sequencing data, Bioinformatics, 31, 166, 10.1093/bioinformatics/btu638 Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 Ramirez, 2014, deepTools: a flexible platform for exploring deep-sequencing data, Nucleic Acids Res., 42, W187, 10.1093/nar/gku365 Morpheus Software: https://software.broadinstitute.org/morpheus/. Kuleshov, 2016, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res., 44, W90, 10.1093/nar/gkw377 Zheng, 2019, Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis, Nucleic Acids Res., 47, D729, 10.1093/nar/gky1094 McLean, 2010, GREAT improves functional interpretation of cis-regulatory regions, Nat. Biotechnol., 28, 495, 10.1038/nbt.1630 Ince, 2016, The endothelium in sepsis, Shock, 45, 259, 10.1097/SHK.0000000000000473 Siddique, 2017, Vascular manifestations in antiphospholipid syndrome (APS): is APS a thrombophilia or a vasculopathy?, Curr. Rheumatol. Rep., 19, 64, 10.1007/s11926-017-0687-z Engel, 2017, Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells, Atherosclerosis Suppl., 30, 141, 10.1016/j.atherosclerosissup.2017.05.039 Velasquez, 2018, Mechanisms of endothelial dysfunction in antiphospholipid syndrome: association with clinical manifestations, Front. Physiol., 9, 1840, 10.3389/fphys.2018.01840 Espinosa, 2011, Management of refractory cases of catastrophic antiphospholipid syndrome, Autoimmun. Rev., 10, 664, 10.1016/j.autrev.2011.04.031 Scoble, 2011, Management of refractory anti- phospholipid syndrome, Autoimmun. Rev., 10, 669, 10.1016/j.autrev.2011.04.030 Mekinian, 2015, Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?, Autoimmun. Rev., 14, 23, 10.1016/j.autrev.2014.08.040 Pericleous, 2013, Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome, Thromb. Haemostasis, 109, 72, 10.1160/TH12-05-0346 Velásquez, 2016, Cuantificación sistematizada de la remodelación vascular in vitro en la morbilidad gestacional asociada al síndrome antifosfolípido, Rev. Chil. Obstet. Ginecolog., 81, 455, 10.4067/S0717-75262016000600002 Agelopoulos, 2006, Epigenetic determination of a cell-specific gene expression program by ATF-2 and the histone variant macroH2A, EMBO J., 25, 4843, 10.1038/sj.emboj.7601364 Vlachoyiannopoulos, 2003, Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study, Rheumatology (Oxford), 42, 645, 10.1093/rheumatology/keg182 D'Angelo, 2019, Antiphospholipid antibodies overlapping in isolated neurological syndrome and multiple sclerosis: neurobiological insights and diagnostic challenges, Front. Cell. Neurosci., 1 3, 107, 10.3389/fncel.2019.00107 Cartin-Ceba, 2014, Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage, Arthritis Care Res., 66, 301, 10.1002/acr.22109 Rodríguez, 2021, Antiphospholipid antibodies from women with pregnancy morbidity and vascular thrombosis induce endothelial mitochondrial dysfunction, mTOR activation, and autophagy, Front. Physiol., 12, 10.3389/fphys.2021.706743 Canaud, 2014, Christophe legendre, and fabiola terzi, N. Engl. J. Med., 371, 303, 10.1056/NEJMoa1312890 Martirosyan, 2015, Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome, BioMed Res. Int., 2015, 10.1155/2015/292851